Physician profile
Alfred Rodriguez
NPI 1942293972
$15,905.05
in general payments reported to CMS, 2019-2025
36 companies · $9,432 in 2025
The $9,432 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $368 · 2021: $535 · 2022: $1,001 · 2023: $1,909 · 2024: $2,006 · 2025: $9,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,018 · Consulting Fee: $4,500 · Travel and Lodging: $1,443 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,018.05 |
| Consulting Fee | $4,500.00 |
| Travel and Lodging | $1,442.73 |
| Education | $385.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $7,716.29 | 2023-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $1,396.85 | 2020-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $741.18 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $607.51 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $585.85 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $491.40 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $450.69 | 2019-2025 | Veltassa |
| Ardelyx, INC. | $388.21 | 2023-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $365.67 | 2024-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $326.71 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $313.00 | 2019-2024 | Ultomiris |
| Calliditas Therapeutics US INC. | $298.31 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $297.48 | 2022-2025 | Lupkynis |
| Baxter Healthcare | $247.05 | 2019-2024 | Renal - Pd |
| Novartis Pharmaceuticals Corporation | $211.63 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $186.90 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $179.49 | 2019 | |
| Glaxosmithkline, LLC. | $167.98 | 2021-2025 | Benlysta, Arexvy, Shingrix |
| Scpharmaceuticals INC. | $115.65 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $106.11 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.88 | 2023-2025 | Jardiance |
| Renalytix Ai, INC. | $99.58 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Arbor Pharmaceuticals, INC. | $76.19 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $70.40 | 2019-2024 | |
| Lilly USA, LLC | $59.31 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $56.27 | 2025 | Korlym |
| Apellis Pharmaceuticals, INC. | $49.42 | 2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $46.58 | 2021 | |
| Azurity Pharmaceuticals, INC. | $42.82 | 2023-2025 | Edarbi |
| Kyowa Kirin, INC. | $34.96 | 2023 | Crysvita |
| Vantive US Healthcare LLC | $31.60 | 2025 | Renal - Pd |
| Hikma Pharmaceuticals USA | $23.57 | 2019 | |
| Akebia Therapeutics INC | $16.51 | 2019-2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.